142 related articles for article (PubMed ID: 17348447)
1. Melanoma inhibiting activity protein (MIA), beta-2 microglobulin and lactate dehydrogenase (LDH) in metastatic melanoma.
Cao MG; Auge JM; Molina R; Martí R; Carrera C; Castel T; Vilella R; Conill C; Sánchez M; Malvehy J; Puig S
Anticancer Res; 2007; 27(1B):595-9. PubMed ID: 17348447
[TBL] [Abstract][Full Text] [Related]
2. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of multiple serum markers in advanced melanoma.
Díaz-Lagares A; Alegre E; Arroyo A; González-Cao M; Zudaire ME; Viteri S; Martín-Algarra S; González A
Tumour Biol; 2011 Dec; 32(6):1155-61. PubMed ID: 21858537
[TBL] [Abstract][Full Text] [Related]
4. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma.
Deichmann M; Benner A; Bock M; Jäckel A; Uhl K; Waldmann V; Näher H
J Clin Oncol; 1999 Jun; 17(6):1891-6. PubMed ID: 10561230
[TBL] [Abstract][Full Text] [Related]
5. Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients.
Sanmamed MF; Fernández-Landázuri S; Rodríguez C; Lozano MD; Echeveste JI; Pérez Gracia JL; Alegre E; Carranza O; Zubiri L; Martín-Algarra S; González A
Clin Chim Acta; 2014 Feb; 429():168-74. PubMed ID: 24333389
[TBL] [Abstract][Full Text] [Related]
6. Impact of lymph node metastases on serum level of melanoma inhibitory activity in stage III melanoma patients.
Hofmann MA; Schicke B; Fritsch A; Biesold S; Gussmann F; Küchler I; Voit C; Trefzer U
J Dermatol; 2011 Sep; 38(9):880-6. PubMed ID: 21658116
[TBL] [Abstract][Full Text] [Related]
7. The value of melanoma inhibitory activity and LDH with melanoma patients in a Chinese population.
Li C; Liu J; Jiang L; Xu J; Ren A; Lin Y; Yao G
Medicine (Baltimore); 2021 Feb; 100(8):e24840. PubMed ID: 33663104
[TBL] [Abstract][Full Text] [Related]
8. S-100B protein and melanoma inhibitory activity protein in uveal melanoma screening. A comparison with liver function tests.
Missotten GS; Korse CM; van Dehn C; Linders TC; Keunen JE; Jager MJ; Bonfrer JM
Tumour Biol; 2007; 28(2):63-9. PubMed ID: 17264538
[TBL] [Abstract][Full Text] [Related]
9. S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase.
Krähn G; Kaskel P; Sander S; Waizenhöfer PJ; Wortmann S; Leiter U; Peter RU
Anticancer Res; 2001; 21(2B):1311-6. PubMed ID: 11396205
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Serum Tumor Markers S100 and Melanoma-inhibitory Activity (MIA) in the Monitoring of Patients with Metastatic Melanoma Receiving Vaccination Immunotherapy with Dendritic Cells.
Uslu U; Schliep S; Schliep K; Erdmann M; Koch HU; Parsch H; Rosenheinrich S; Anzengruber D; Bosserhoff AK; Schuler G; Schuler-Thurner B
Anticancer Res; 2017 Sep; 37(9):5033-5037. PubMed ID: 28870930
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of melanoma inhibiting activity levels in malignant melanoma.
Meral R; Duranyildiz D; Tas F; Camlica H; Yasasever V; Kurul S; Dalay N
Melanoma Res; 2001 Dec; 11(6):627-32. PubMed ID: 11725209
[TBL] [Abstract][Full Text] [Related]
12. Comparison of two prognostic markers for malignant melanoma: MIA and S100 beta.
Juergensen A; Holzapfel U; Hein R; Stolz W; Buettner R; Bosserhoff A
Tumour Biol; 2001; 22(1):54-8. PubMed ID: 11054027
[TBL] [Abstract][Full Text] [Related]
13. Results of the determination of serum markers in patients with malignant melanoma.
Lugović L; Situm M; Buljan M; Poduje S; Sebetić K
Coll Antropol; 2007 Jan; 31 Suppl 1():7-11. PubMed ID: 17469741
[TBL] [Abstract][Full Text] [Related]
14. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.
Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A
Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447
[TBL] [Abstract][Full Text] [Related]
15. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
[TBL] [Abstract][Full Text] [Related]
16. Clinical value of protein S100 and melanoma-inhibitory activity (MIA) in malignant melanoma.
Tas F; Yasasever V; Duranyildiz D; Camlica H; Ustuner Z; Aydiner A; Topuz E
Am J Clin Oncol; 2004 Jun; 27(3):225-8. PubMed ID: 15170138
[TBL] [Abstract][Full Text] [Related]
17. [Protein S100 beta and Melanoma Inhibitory Activity (MIA): a prospective study of their clinical value for the early detection of metastasis in malignant melanoma].
Loppin M; Quillien V; Adamski H; Ollivier I; Garlantézec R; Chevrant-Breton J
Ann Dermatol Venereol; 2007; 134(6-7):535-40. PubMed ID: 17657179
[TBL] [Abstract][Full Text] [Related]
18. Serum markers to detect metastatic uveal melanoma.
Barak V; Frenkel S; Kalickman I; Maniotis AJ; Folberg R; Pe'er J
Anticancer Res; 2007; 27(4A):1897-900. PubMed ID: 17649791
[TBL] [Abstract][Full Text] [Related]
19. [Serum markers for melanoma].
Ugurel S
Hautarzt; 2005 Feb; 56(2):173-84; 185-6. PubMed ID: 15657726
[TBL] [Abstract][Full Text] [Related]
20. Plasma markers for identifying patients with metastatic melanoma.
Kluger HM; Hoyt K; Bacchiocchi A; Mayer T; Kirsch J; Kluger Y; Sznol M; Ariyan S; Molinaro A; Halaban R
Clin Cancer Res; 2011 Apr; 17(8):2417-25. PubMed ID: 21487066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]